Protocol Ledger

NCT07255404 · Phase II · RECRUITING

A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Interventional Phase II clinical trial protocol NCT07255404 sponsored by BioNTech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-04 Enrollment: 105 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07255404
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)105 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07255404
Protocol FieldVerified Registry Value
NCT IdentifierNCT07255404
Consolidated Lead SponsorBioNTech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment105 participants (ESTIMATED)
Registered Start Date2025-12-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07255404
Hospital Research SiteLocationSite Profile
The Alfred HospitalMelbourne, AustraliaOpen Hospital Dossier ->
Jilin Cancer HospitalChangchun, ChinaOpen Hospital Dossier ->
Sichuan Cancer HospitalChengdu, ChinaOpen Hospital Dossier ->
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen UniversityGuangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI